Finance

Beta
Lists
SNDX:NASDAQ
Syndax Pharmaceuticals Inc
$19.32
0.00%
(0.00) 1D
$18.97
-1.81% (-0.35)
Pre-market
Closed: Jun 22, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SNDX...
Mkt. cap
1.71B
Avg. vol.
1.83M
Volume
208.00
52-wk high
$25.59
52-wk low
$8.58
EPS
-$2.80
Beta
0.38
Shares outstanding
88.61M
No. of employees
298
Mkt. cap
1.71B
Avg. vol.
1.83M
Volume
208.00
52-wk high
$25.59
52-wk low
$8.58
EPS
-$2.80
Beta
0.38
Shares outstanding
88.61M
No. of employees
298
News stories
From sources across the web
About Syndax Pharmaceuticals Inc
CEO-
Employees298
Founded2005
Headquarters-
SectorBiotechnology
Websitesyndax.com
Analyst Ratings
Based on 10 analysts giving stock ratings to SNDX in the past 3 months
Strong Buy
Buy
10
Hold
0
Sell
0
12 month forecast
Based on 10 Wall Street analysts offering 12 month price targets for SNDX in the last 3 months.
Highest
Current $19.32
$46.00 (+138.10%)
Average
$37.11 (+92.08%)
Lowest
$29.00 (+50.10%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Stephen Willey
Stifel Nicolaus
Buy
Maintained
$46.00
+138.1%
06/15/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
$40.00
+107%
06/15/2026
Bradley Canino
Guggenheim
Buy
Maintained
$31.00
+60.5%
06/12/2026
Corinne Johnson
Goldman Sachs
Buy
Maintained
$34.00
+76%
06/03/2026
Jason Zemansky
Bank of America Securities
Buy
Maintained
$29.00
+50.1%
05/21/2026
David Dai
UBS
Buy
Maintained
$37.00
+91.5%
05/13/2026
Faisal Khurshid
Jefferies
Buy
Maintained
$37.00
+91.5%
05/01/2026
Etzer Darout
Barclays
Buy
Maintained
$37.00
+91.5%
05/01/2026
Phil Nadeau
TD Cowen
Buy
Maintained
-
-
04/30/2026
Unknown Analyst
Jefferies
Buy
Maintained
$40.00
+107%
03/30/2026
Unknown Analyst
Mizuho Securities
Buy
Maintained
$43.00
+122.6%
03/30/2026
Salim Syed
Mizuho Securities
Buy
Maintained
$43.00
+122.6%
03/30/2026
Anupam Rama
J.P. Morgan
Buy
Maintained
$45.00
+132.9%
03/09/2026
Yigal Nochomovitz
Citi
Buy
Maintained
$57.00
+195%
03/02/2026
Last report
Apr 30, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.48 / -$0.60
+19.45%beat
Revenue / Est. (USD)
64.86M / 69.74M
-6.99%miss
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
37.96M
45.87M
68.73M
64.86M
Cost of goods sold
63.51M
58.38M
81.35M
2.63M
Cost of revenue
63.51M
58.38M
81.35M
2.63M
Research and development expenses
-
-
-
58.84M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
43.80M
44.92M
49.93M
37.59M
Operating expense
43.80M
44.92M
49.93M
96.43M
Total operating expenses
107.31M
103.30M
131.28M
99.07M
Operating income
-69.35M
-57.43M
-62.55M
-34.20M
Other non operating income
-586.00K
-275.00K
-201.00K
-186.00K
EBT including unusual items
-71.85M
-60.72M
-68.01M
-42.67M
EBT excluding unusual items
-71.85M
-60.72M
-68.01M
-42.67M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-71.85M
-60.72M
-68.01M
-42.67M
Net profit margin
-189.28%
-132.36%
-98.96%
-65.79%
Earnings per share
-0.83
-0.70
-0.78
-0.48
Interest and investment income
5.95M
5.27M
4.33M
3.56M
Interest expense
-7.86M
-8.28M
-9.59M
-11.85M
Net interest expenses
-1.91M
-3.01M
-5.26M
-8.28M
Depreciation and amortization charges
-
-
-
-
EBITDA
-69.35M
-57.42M
-62.54M
-34.20M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer